Introduction
Mesenchymal stromal cells (MSCs) from bone marrow and other tissues have the capacity to differentiate to chondrocytes. The differentiated cell phenotype has been well characterized and shares many cellular and extracellular matrix (ECM) features of primary chondrocytes isolated from articular cartilage. MSCs can also be prepared from induced pluripotent stem cells iPSCs) generated from dermal fibroblasts or other cells and can also form chondrocytes.
Our objective in this study was to assess whether analysis of the differentiated phenotype in cells from patients with osteoarthritis (OA) would shed light on the cellular pathology of the disease. Idiopathic OA occurs widely and has a broad spectrum of symptoms and probably a broad spectrum of causation, making interpretation of results in studies such as this potentially difficult. We therefore selected a monogenic disease, familial osteochondritis dissecans (FOCD), associated with a known single mutation and characterized by the development of early and severe OA. We isolated MSCs and generated iPSCs from FOCD patients and assessed their chondrogenic differentiation in an attempt to shed light on the cellular pathology that gives to the unstable and rapidly degenerating articular cartilage in these patients.
Osteochondritis dissecans (OCD) is a serious disease of joints characterized by separation of articular cartilage from subchondral bone [1, 2] . The most commonly affected joints are the knee, elbow and ankle, but other joints may be involved [3] [4] [5] [6] [7] . Symptoms include pain on activity, effusion, crepitation and limited range of movement [8] . Development of degenerative osteoarthritis (OA) is common in patients with OCD [9] . FOCD has been reported on a number of occasions where an underlying hereditary factor exists [10] [11] [12] [13] . This study focuses on a family from Northern Sweden, first reported by Stougaard in 1964 [13] , with FOCD (referred to as FOCD-NS) inherited in an autosomal dominant pattern [12] . The results of a genome-wide scan and DNA sequencing showed that all affected family members bear a heterozygous G-A mutation in aggrecan exon 17, which results in a Val-Met amino acid replacement (V2303M) in the G3 aggrecan C-type lectin domain (CLD) [14] .
Aggrecan, a major proteoglycan of articular cartilage produced by chondrocytes, has a large protein core richly substituted with sulfated glycosaminoglycan (GAG) chains. The aggrecan protein core follows the secretory pathway within the chondrocyte; it is made in the rough endoplasmic reticulum (rER) and then translocated to the Golgi for GAG chain synthesis and sulfation, prior to secretion to the extracellular matrix (ECM) [15] . The unique structure, its high concentration within the ECM, and its ability to form a supermolecular complex with hyaluronan and bind to other matrix proteins all profoundly influence the biomechanical properties of the tissue [16] . Deletion of aggrecan G3 domain in a mutant chick (nanomelia) was found to block aggrecan secretion from chondrocytes [17] . Further evidence using aggrecan synthesised with no naturally folded G3 also indicated a role for this domain in intracellular trafficking and secretion. [18] . An important function of the G3 CLD domain is binding to tenascin-C, tenascin-R, fibulin-1, and fibulin-2 in cartilage ECM [19] and human aggrecan constructs carrying the V2303M mutation were shown to have diminished interactions with these binding partners [14] .
We cultured mesenchymal stromal cells (MSCs) from bone marrow (BM) of an FOCD-NS patient and induced them to differentiate into chondrocytes [20] . Analysis of the phenotype of differentiated cells revealed an abnormal intracellular processing pathway and limited extracellular distribution of aggrecan. Furthermore, we showed that the mutated aggrecan caused morphological changes in the rER within the chondrocytes. Our experiments suggested a cellular pathology of FOCD-NS with misfolded aggrecan accumulating inside the rER, resulting in ER stress and leading to a deficiency of cell function in protein secretion. As a consequence, there was defective development of the cartilaginous ECM, with a distinctly abnormal composition of key proteins and proteoglycans. This suggested that, in addition to defective aggrecan processing, synthesis and assembly of the entire ECM is impaired.
To further extend our observations, we prepared patient-specific induced pluripotent stem cells (iPSCs) with successful reprogramming of skin fibroblasts from two FOCD-NS patients.
By exploiting the potential of iPSCs when implanted in vivo to form teratomas with tissues from all three germ layers, including cartilage, we were able to show that the same disease phenotype was recapitulated in the iPSC-derived cartilage within teratomas. These results provide new insight into the cellular phenotype of FOCD and demonstrate for the first time a disease model of a monogenic OA based on patient specific iPSCs.
Materials and Methods

Ethical approvals
All animal experimentation complied with institutional guidelines and had ethical approval 
Tissue samples
A BM sample was obtained from a 49-year-old male FOCD-NS patient during joint replacement surgery and normal human BM-MSC (053) were isolated from a 33-year-old male healthy donor. Dermal fibroblasts were obtained from a 25-year-old son (FOCD-NS1) and 49year-old mother (FOCD-NS2) for generation of patient-derived iPSC. An iPSC line (33D-6) from a healthy donor (56-year-old male) was obtained from Dr Gareth Sullivan (University of Edinburgh, UK) [21] .
Isolation and characterization of MSCs from patient and control marrow
BM-MSCs were isolated and characterized (adipogenesis and osteogenesis) as previously described [20] . To assess positive and negative surface markers of BM-MSCs, the Human MSC Analysis Kit (BD Bioscience) was used according to the manufacturer's protocol. Data was analysed by FlowJo 6.0.
Chondrogenesis of BM-MSCs
To detect the disease phenotypes, chondrogenesis of BM-MSCs was performed using micropellet culture as described previously [20] . As the brief centrifugation step associated with micropellet formation affected the structure of pellets derived from patient cells, a modified high cell density micromass method was performed as previously described [22, 23] . Briefly, 2 X 10 5 of BM-MSCs in 10 µl was incubated at 37°C for 2 hours in low adherent round bottom 96-well plates (Sigma). 200µl of MSC maintenance medium was then added into each well, followed by overnight incubation. Medium was replaced by chondrogenic medium with 10 ng/ml TGF-β3 [20] at day 2 and was changed at every second day.
Micropellets and micromass cultures were harvested at different time points.
Sulphated glycosaminoglycan (GAG) and DNA quantification
For quantification of GAG, dimethylmethylene blue (DMMB) was performed as described previously [20] . DNA was measured by PicoGreen® dsDNA assay kit (Invitrogen), according to the manufacturer's protocol. To assess the chondrogenic capability of control and FOCD-NS cells, the ratio of GAG to DNA was calculated.
Histological and immunohistochemical analysis of chondrogenic pellets
Samples were processed as previously described [20] . For detection of GAG, sections were stained with 0.5% toluidine blue (pH8) for 5 minutes at 60°C. Immuno-staining was performed to investigate the distribution of ECM proteins (collagen type II and aggrecan) and co-localization of aggrecan and glucose regulated protein (GRP78) in chondrogenic pellets and cultures. Detailed experimental procedures can be found in supplemental data.
Brightfield and confocal microscopy were used to examine the immunohistochemical and immunofluorescence stained specimens. The magnified images for detection of cell morphology and ECM distribution were created by ImageJ.
Transmission electron microscopy (TEM)
To analyse ECM formation and ultrastructure of ER, day 56 micromass cultures were processed for TEM examination as previously described [24] Samples were examined using the Hitachi H7000 transmission electron microscope.
To estimate the volume fraction (Vv) of rER to cell cytoplasm, a systematic random sampling protocol was adopted. This consisted of a series of images (10) taken across the pellet at an initial magnification of 3,000X. Three further images were taken from each field at a magnification 10,000X. Simple point counting methods were used to estimate cellular composition [25] .
Mass spectrometry
For sample preparation, a modified protocol for extracting peptides from chondrogenic pellets derived from BM-MSCs was performed based on a previous description [26] . Detailed experimental procedures can be found in supplemental data. Each sample was run in technical duplicate. The measured peptide transitions are listed in Supplemental Table 3 .
Three to six transitions for each peptide were measured in a scheduled multiple reaction monitoring method [26] . Briefly, the amount of each protein was normalized by the pellet volume. The mean ratios of ECM proteins between FOCD and control BM-MSC derived pellets were calculated.
iPSC generation and characterization
For reprogramming, isolated skin fibroblasts from two patients (FOCD-NS1 and FOCD-NS2)
were transfected by retrovirus containing the four Yamanaka reprogramming factors as described previously [27] . Resulting iPSC colonies were expanded. To assess the pluripotency of these iPSCs, semiquantitative RT-PCR, immunocytochemistry, flow cytometry, teratoma formation in vivo, karyotype analysis and mutation verification were performed. See supplemental data for detailed protocols.
Verification of disease phenotype in iPSC-derived cartilage
Cartilaginous nodules formed in teratoma derived from one control and four FOCD-NS iPSC lines were studied. To identify cartilage tissues in teratoma sections, samples were stained with 0.02% fast green solution followed by 0.1% safranin-O solution. Cartilage tissue appeared red and non-cartilage tissues showed green. To study the distribution of aggrecan protein in these tissue, immunohistochemical staining was performed. Detailed experimental procedures can be found in supplemental data.
Results
FOCD-NS MSC characterization
MSCs isolated from bone marrow of a FOCD-NS patient were morphologically similar to cells from a healthy donor ( Figure 1A control MSCs were assessed for multipotency using trilineage differentiation tests. Both populations showed a capacity to differentiate into osteoblasts and adipocytes ( Figure 1C ). In contrast, there were marked differences between patient and control cells in chondrogenic pellet cultures. Both MSC populations readily formed white cartilaginous pellets, but patient samples had an irregular discoid morphology (Figure 2A and B). Patient pellets (diameter 1.5-2mm) were larger with a rough surface compared to the smooth glistening surface of control pellets (diameter 1-1.5mm). In addition, there was greater GAG staining in the FOCD-NS pellets ( Figure 2B ).
Characterization of chondrogenic cultures
Immunohistochemical staining of chondrogenic pellets was performed using an antibody specific for the interglobular domain (IGD) of aggrecan. In control pellets, aggrecan was clearly discernible within the chondrocytes and throughout the matrix; staining was primarily intracellular at early time points and progressed through pericellular localisation evident from day 5 to intraterritorial distribution by day 14 ( Figure 2C , left panel). In contrast, in the patient pellets aggrecan staining was predominantly cellular or pericellular with minimal territorial or intraterritorial matrix staining at 14 days. At earlier times, some aggrecan was detected in the extracellular matrix, perhaps reflecting the heterozygous nature of the FOCD-NS mutation, but this diminished by day 5 in culture ( Figure 2C , right panel). This result suggested that the effect of the mutation within the CLD domain was to impede normal processing and stabilization of aggrecan within the ECM.
To allow careful comparison between patient and control cells we used micromass cultures without centrifugation. Micromass culture allows self-assembly of cells at high density into organized aggregates and may allow for better cell-cell contact, thus facilitating chondrogenic differentiation more typically seen during development [22] . To reflect the adult onset of the condition, micromass cultures were maintained for periods of time between 14 and 100 days.
Histological analysis showed that patient cells were able to form regular spherical micromass cultures of larger dimension than those derived from control cells ( Figure 3A ). We carried out co-staining for aggrecan protein and the glucose-regulated protein (GRP78), a rER chaperone [28] . Immunostaining of micromass pellets from day 42 showed the patient sample had a lower density of collagen type II fibres than found in the control sample ( Figure 4D ).
Quantitative analysis of ECM proteins
We analyzed the protein, proteoglycan and collagen composition of ECM generated by chondrocytes differentiated from patient marrow-derived MSCs compared to controls. These analyses were performed using guanidinium hydrochloride extracts of pellets and included both intracellular and extracellular components. There were marked differences which pointed to a highly dysregulated matrix assembly in patient cells ( Figure 5 and Supplemental Table 3 ). Firstly, we noted a reduction of approximately 50% in aggrecan content in patient cells, while the hyaluronan proteoglycan link protein was increased approximately 1.7 fold.
The peptide analysis used in these measurements did not include the mutated region of the patient aggrecan G3 domain. Nine common small leucine-rich proteoglycans (SLRPs) were analysed. Of these, asporin (class 1 SLRP), osteoadherin (class 2 SLRP) and mimecan (class 3 SLRP) were dramatically upregulated in patient cells. These three proteins have all been linked to mineralization [29, 30] often seen in OA [31] . The proteoglycans versican and perlecan also clearly increased in patient cultures. Among the glycoproteins analyzed, cartilage oligomeric matrix protein (COMP), fibronectin and tenascin-C were all upregulated dramatically in FOCD-NS, whereas thrombospondin-1 was slightly increased in controls.
Examination of collagen fibres contained in the ECM revealed that patient samples had 2-3-fold higher extractable collagen alpha-3 (VI) and collagen alpha-2(XI), than controls.
However, the amount of collagen alpha-1(II) chain chondrocalcin and collagen alpha-1(II) chain N-propeptide were similar between the two groups. Among other ECM proteins, we found that cartilage intermediate layer protein-2 (CILP-2) was uniquely present in the patient samples (Supplemental Table 3 ), matrilin-3 was expressed 6-fold higher in FOCD-NS, and there was no difference between the two groups in the level of dermatopontin.
Generation and characterization of FOCD-NS specific iPSCs
We generated patient-specific iPSCs from dermal fibroblasts from 2 patients, a son aged 25 
Discussion
We have characterized MSCs taken from the bone marrow of patients with FOCD-NS, carrying a V2303M mutation compared to MSCs from healthy controls. In terms of analysis of cell surface markers and osteogenic and adipogenic differentiation, MSCs from both groups appeared identical ( Figure 1A -C) [32] . As expected, substantial differences were observed in chondrocytes derived from patient compared to control MSCs. Chondrogenic pellets from patient MSCs were irregular, with a "donut" shape rather than a spherical morphology ( Figure 2A ). It was evident that patient chondrocytes rapidly produced abundant GAG chains attached to aggrecan during processing in the Golgi ( Figure 2B ) [15] . This may have resulted from expression of the non-mutated allele. In micromass cultures the FOCD-NS chondrocytes formed uniform spheres ( Figure 3A) , while in conventional pellet cultures they were irregular discoids. This may be a consequence of the inability of the patient cells to resist the mechanical load associated with centrifugation.
Immunostaining showed that aggrecan was clearly distributed throughout the ECM in control chondrocytes but had a sharply cellular distribution in patient chondrocytes, suggesting that in these the processing, assembly and secretion of aggrecan were defective ( Figure 2C ).
Confocal microscopy confirmed this and also appeared that the ECM of patient chondrocytes was devoid of aggrecan ( Figure 3B ). Further, we found that intracellular aggrecan was clearly associated with the ER, indicated by co-staining with the ER marker protein GRP78 ( Figure   3B ). This confirmed a defect in processing of aggrecan associated with retention within the ER and failure to translocate to Golgi and to be secreted. Quantification of GAG and DNA in micromass cultures derived from controls and FOCD-NSs suggested that early intracellular accumulation of aggrecan proteins resulted in enhanced cell proliferation and also reduced chondrogenic capacity ( Figure 4A ). Further evaluation using TEM confirmed the absence of a fibrillar matrix and the presence of an atypical, diffuse ultrastructure within patient chondrocytes ( Figure 4B and Supplemental Figure 1 ). Physically enlarged rER in patient cells further proved that it was packed with protein products during chondrogenesis ( Figure   4B ). All these observations pointed towards a failure of FOCD-NS mesenchymal progenitors to assemble aggrecan within the ER and to secrete it from the cell following differentiation.
Using peptide-specific mass spectrometric analysis, we analysed ECM proteins to determine how they are differently modulated in patient chondrocytes derived from primary MSCs.
There were several striking differences between the patient chondrocytes and those from healthy controls. We found a 50% reduction in aggrecan in patient samples ( Figure 5 and Supplemental Table 3 ), which suggested that the CLD mutation results in attenuated production of aggrecan during the chondrogenic process. Interestingly, versican expression was 6.8 fold higher in patient samples ( Figure 5 and Supplemental Table 3 ). We speculate that this up-regulation may act to compensate for the lack of aggrecan in the ECM or could reflect delayed chondrogenic differentiation. Secondly, a group of proteins associated with cartilage degeneration were highly upregulated in FOCD-NS samples: asporin, mimecan, fibronectin, matrilin-3, COMP, tenascin-C and perlecan ( Figure 5 and Supplemental FOCD-NS samples revealed wide variations in production levels ( Figure 5 and Supplemental Table 3 ). In summary, these results outlined the consequences of early intracellular accumulation of mutated aggrecan, and indicated cartilaginous dysplasia in later chondrogenesis of FOCD-NS samples.
There are two difficulties associated with examination of primary MSCs from patients with FOCD-NS, namely the limited availability of marrow and its abnormal cellularity. Marrow aspirates taken from the patients were white, fatty, and different from healthy marrow. Upon plating, the yield of MSCs was low, although sufficient for the characterization described above. Further characterization required the generation of patient-specific iPSCs. We successfully generated iPSCs from patient fibroblasts ( Figure 6 ) and confirmed that the mutation in exon 17 of the aggrecan gene was preserved ( Figure 6D ).
We looked in detail at cartilage nodules within teratomas derived from FOCD-NS-iPSCs.
Here we found the same disease phenotype observed in chondrogenic cultures of primary MSCs, i.e. rich in GAG but with a distinct lack of aggrecan in the ECM and a pronounced intracellular localization of aggrecan within early and late chondrocytes ( Figure 7 ). This suggested the cartilage derived from reprogrammed patient fibroblasts preserved the disease phenotype and showed the same aberrant aggrecan processing.
Aggrecan G3 domain plays a role in intracellular processing of the core protein and in facilitating its secretion [41] . Our observations of the chondrogenic behaviour of progenitor cells from FOCD-NS patients allow us to draw a number of conclusions about the cellular abnormalities associated with this mutation. It leads to retention of the aggrecan core within the ER of chondrocytes and induces continued ER stress associated with an enlarged structure. This results in abnormal processing and assembly of the ECM, leading to rapid joint destruction and development of OA. This suggests that the mutation promotes a nonreversible cellular pathology during cartilage development.
ER dilation and ER stress, caused by mutations in ECM genes such as COMP, MATN3 and COL2A1, have been associated with the pathology of osteochondrodysplasias [42] . In the future, FOCD-NS iPSCs will be used to study the pathological roles associated with this G3 mutation in inducing ER stress, impacting cell behaviour and disturbing matrix regulation. In terms of development of therapy for FOCD-NS, these cells may be used in the development of drugs to restore cellular function or retard OA development. Furthermore, correction of the mutation in FOCD-NS-iPSCs using gene editing strategies may lead to a corrective cellular therapy for these patients.
Conclusion
In our current study, we have conducted research to investigate the molecular pathologies of FOCD-NS, which results in disproportionate growth, disturbed chondro-skeletal development and early onset OA.
Studying chondrocytes differentiated from patients' bone marrow mesenchymal stromal cells and iPSCs, we found large dysregulation and aberration in assembled extracellular matrix and irregulated cell fate, as consequences of endoplasmic reticulum stress, which was caused by an abnormal accumulation of mutated aggrecan protein. Immunohistochemistry was performed to investigate the distribution of collagen type II and aggrecan in chondrogenic pellets as described previously, with minor modifications [1] . For the detection of collagen type II, sections were treated with 4mg/ml Pepsin (Dako S3002) for 30 minutes at RT and for the detection of aggrecan, sections were incubated in 10mM sodium citrate (Sigma) pH 6.0 at 97°C for 20 minutes, followed by treatment with 40mU/ml chondroitinase ABC (Sigma) at 37°C for 30 minutes for antigen retrieval. Collagen type II and aggrecan were then detected using a biotin-streptavidin-peroxidase kit for mouse primary antibody (KPL) and employing a mouse anti-aggrecan antibody and a mouse anti-collagen type II antibody as primary antibodies at 4°C overnight. Signal was developed using diaminobenzidine (DAB) substrate kit (Abcam).
Multiple immunofluorescent staining of aggrecan and glucose regulated protein (GRP78) was performed to identify the intracellular location of aggrecan protein.
Sections were incubated with a premixed primary antibody solution, containing mouse anti-aggrecan antibody and rabbit anti-GRP78 antibody, at 4°C overnight followed by a premixed secondary antibody solution, containing Rhodamine (TRITC)-goat anti-mouse and DyLight 488-goat anti-rabbit for one hour at RT.
Negative controls were performed with secondary antibody(s) only and detailed information of the antibodies used is listed in Supplementary Table 1 .
Mass spectrometry analysis
For sample preparation, a modified protocol for extracting peptides from chondrogenic pellets derived from BM-MSCs was performed based on the previous description [2] . Briefly, three day 100 pellets per group, formed in micromass culture,
were extracted with 100 µl of chaotropic extraction buffer (4M GdnHCl, 50mM
sodium acetate, 100mM 6-aminocaproic acid, 5mM benzamidine, 5mM N- Teratoma formation and tissue preparation. Cells for injection were prepared as described previously [3, 4] . Briefly, iPSCs were cultured to 90% confluence. Karyotype analysis. For karyotype analysis, chromosomal spreads were prepared as previously described [5] . Briefly, iPSCs were treated with 0.1µg/ml colcemid Mutation validation. Genomic DNA was extracted from cells using DNeasy Blood & Tissue Kits (Qiagen). Primer sequences to amplify exon 17 of ACAN were as described previously [6] . PCR products were purified by Gel Extraction Kit (Qiagen). 
Graphical abstract legend:
Patients with familial osteochondritis dissecans (FOCD) carry a heterozygous mutation in the ACAN gene, which results in a Val-Met replacement in the C-type lectin domain of aggrecan protein.
Studying a stem cell-derived FOCD chondrogenic model, we found the mutation resulted in unfolded aggrecan protein which accumulated in the endoplasmic reticulum (ER). The overloaded ER influenced the function of FOCD chondrocytes and lead to defective extracellular matrix (ECM) formation. Disease phenotype has been validated with FOCD models derived from bone marrowderived mesenchymal stromal cells (BM-MSCs) and induces pluripotent stem cells (iPSCs).
